UPDATE - UBS Initiates Coverage on JDS Uniphase (JDSU) with a Buy; Diversified Market Leader, But Patience Required
Get Alerts JDSU Hot Sheet
Price: $10.87 --0%
Rating Summary:
10 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Rating Summary:
10 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Join SI Premium – FREE
UPDATE - UBS initiates coverage on JDS Uniphase (Nasdaq: JDSU) with a Buy rating. PT $13.
UBS analyst said, "JDSU is a diversified market leader selling communications test equip. (~45% of sales), optical components and lasers (42% of sales), and other advanced optical technologies (13%). It leads across many of its product end markets, including fiber test eqpt., ROADMs, and tunable XFPs. Its customers include service providers (~75-80% of sales), enterprises, network equip manufacturers and govts."
"$13 target is based on 14x our FY13 EPS estimate of $0.93. While JDSU is in the midst of an inventory correction, we see valuation as attractive at ~11.5x P/E vs. 15x avg in last yr and a 3% discount vs. 19% premium to S&P 500."
To see more ratings on JDSU, Click Here
UBS analyst said, "JDSU is a diversified market leader selling communications test equip. (~45% of sales), optical components and lasers (42% of sales), and other advanced optical technologies (13%). It leads across many of its product end markets, including fiber test eqpt., ROADMs, and tunable XFPs. Its customers include service providers (~75-80% of sales), enterprises, network equip manufacturers and govts."
"$13 target is based on 14x our FY13 EPS estimate of $0.93. While JDSU is in the midst of an inventory correction, we see valuation as attractive at ~11.5x P/E vs. 15x avg in last yr and a 3% discount vs. 19% premium to S&P 500."
To see more ratings on JDSU, Click Here
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CIBC Starts Cadillac Mines Corp (CADY:CN) at Outperformer
- UBS Starts Food Empire (FEH:SP) at Buy
- Wedbush Starts Aktis Oncology (AKTS) at Outperform
Create E-mail Alert Related Categories
New CoverageRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share